Swedbank AB Trims Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Swedbank AB lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 19.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 780,486 shares of the medical research company’s stock after selling 189,026 shares during the period. Swedbank AB’s holdings in Edwards Lifesciences were worth $57,779,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Harbor Capital Advisors Inc. grew its stake in Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after acquiring an additional 273 shares in the last quarter. Nordea Investment Management AB lifted its position in Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its position in Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares during the last quarter. Avanza Fonder AB bought a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $4,845,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Edwards Lifesciences by 9.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock valued at $31,571,000 after purchasing an additional 40,348 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 1.9 %

Shares of Edwards Lifesciences stock opened at $71.21 on Thursday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $72.37 and its two-hundred day simple moving average is $70.06. The company has a market cap of $42.00 billion, a P/E ratio of 10.28, a PEG ratio of 3.54 and a beta of 1.11. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Analysts Set New Price Targets

EW has been the subject of several research analyst reports. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Stifel Nicolaus lifted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Barclays boosted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Truist Financial restated a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, The Goldman Sachs Group boosted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $78.48.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,000 shares of company stock valued at $2,195,180. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.